Oncology Venture har bekräftat registreringsstrategin för dovitinib och utvecklat ny DRP-kombinationsbiomarkör för PD1 / PD-L1 + dovitinib – inleder utlicensieringsaktiviteter med Destum Partners

    NEXT STORY
    Short report of the status of the review in Oasmia
    PREV STORY
    Sandoz resubmits biosimilar pegfilgrastim application to US FDA
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Helix BioPharma Corp. Closes Final Tranche of Private Placement

    CAD2,262,000 in total private placement financings closed in December 2018 for a total of ...

    author_avatar
    NASDAQ Market News

    Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

    author_avatar
    NASDAQ Market News

    PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline

    author_avatar
    NASDAQ Market News